Generalised urticaria and angioedema complicating switch back from subcutaneous to intravenous vedolizumab therapy.
Chauhan D., Prabhu A., Cripps S., Misbah S., Griffiths K., Roseman A., Walsh A., Satsangi J.
We report a unique case of a 34-year-old man with ulcerative colitis, previously in complete remission with intravenous vedolizumab monotherapy, who developed an urticarial injection-site reaction on switching to a subcutaneous preparation and thereafter experienced a new hypersensitivity reaction on switch back to intravenous vedolizumab, necessitating complete discontinuation from this drug. This case highlights the need for vigilance on switching back to intravenous preparations of vedolizumab, in response to injection-site reactions with a subcutaneous preparation, even if the intravenous preparation had been previously well tolerated by the patient.